Streetbeat News

Price Targets

LXP

Keybanc analyst Todd Thomas has maintained an Overweight rating on LXP Industrial Trust (NYSE:LXP) but reduced the price target from $12 to $11.

Portfolio Pulse from Benzinga Newsdesk

December 13, 2023 | 10:36 am

DRI

Keybanc analyst Eric Gonzalez has maintained an Overweight rating on Darden Restaurants (NYSE:DRI) and increased the price target from $175 to $177.

Portfolio Pulse from Benzinga Newsdesk

December 13, 2023 | 10:34 am

CCCS

Citigroup analyst Tyler Radke has reinstated CCC Intelligent Solutions (NASDAQ:CCCS) with a Neutral rating and set a price target of $13.

Portfolio Pulse from Benzinga Newsdesk

December 13, 2023 | 10:31 am

VZIO

B. Riley Securities analyst Daniel Day has initiated coverage on VIZIO Holding Corp (VZIO) with a Buy rating and set a price target of $11.

Portfolio Pulse from Benzinga Newsdesk

December 13, 2023 | 10:29 am

LULU

Telsey Advisory Group analyst Dana Telsey has maintained an Outperform rating on Lululemon Athletica (NASDAQ:LULU) and increased the price target from $520 to $550.

Portfolio Pulse from Benzinga Newsdesk

December 13, 2023 | 10:11 am

DV

Morgan Stanley analyst Matthew Cost has initiated coverage on DoubleVerify Holdings (NYSE:DV) with an Overweight rating and set a price target of $40.

Portfolio Pulse from Benzinga Newsdesk

December 13, 2023 | 10:07 am

CWH

Roth MKM analyst Scott Stember has initiated coverage on Camping World Holdings (NYSE:CWH) with a Buy rating and set a price target of $30.

Portfolio Pulse from Benzinga Newsdesk

December 13, 2023 | 10:02 am

SXI

DA Davidson analyst Michael Shlisky has initiated coverage on Standex International (NYSE:SXI) with a Buy rating and set a price target of $165.

Portfolio Pulse from Benzinga Newsdesk

December 13, 2023 | 10:00 am

DNLI

Citigroup analyst David Hoang has initiated coverage on Denali Therapeutics with a Buy rating and set a price target of $32. The coverage is likely to influence investor sentiment and could impact Denali's stock price in the short term.

Portfolio Pulse from Benzinga Newsdesk

December 13, 2023 | 9:52 am

NBIX

Citigroup analyst David Hoang has initiated coverage on Neurocrine Biosciences (NBIX) with a Neutral rating and set a price target of $127.

Portfolio Pulse from Benzinga Newsdesk

December 13, 2023 | 9:46 am